Our group aims to gain a better understanding of the clinical characteristics and mechanisms of progression and therapeutic resistance of hematological tumors with a focus on multiple myeloma and aggressive T and B lymphomas to propose new therapeutic strategies.
The lab is interested in improving the understanding of the molecular mechanisms leading to the progression and therapeutic resistance of multiple myeloma, including extramedullary disease, Hodgkin lymphoma and aggressive non-Hodgkin B and T lymphomas.
To develop these lines of research, we use patient samples and advanced preclinical models for therapeutic, mechanistic and functional studies. We have developed the technology to generate murine models derived from patients by orthotopic implantation (orthotopic PDX) and 2D/3D cultures that we can humanize using components of the human immune system (from the same patient from whom the model has been derived, when possible). Additionally, we are involved in a project that is developing humanized nanomedicines as a new therapeutic strategy for acute myeloid leukemia.
Our group is integrated by professionals from the Clinical Hematology Service of ICO/Hospitalet, the ProCURE/ICO Program and the Pathology Service of the Hospital of Bellvitge. Within the Hematology Service of the ICO Hospitalet, one of our main objectives is to promote translational research training for the professionals of the Service, generating opportunities for the completion of doctoral theses and stimulating new scientific leadership as well as to attract talent with a mixed clinical/researcher profile for the Service.
Group members
Principal Researcher
Principal Researcher
Principal Researcher
Principal Researcher
Principal Researcher
Clinical collaborator
Clinical collaborator
Clinical collaborator
Clinical collaborator
Predoctoral researcher
Posdoctoral researcher
Publications
JAMA Oncol. 2022 Jan 1;8(1):114-122. doi: 10.1001/jamaoncol.2021.6199. ABSTRACT IMPORTANCE: Whether the severity and mortality of COVID-19 in patients with cancer have improved in terms of disease management and capacity is yet to be defined. OBJECTIVE: To test whether severity and mortality from COVID-19 among patients with cancer have improved during the course of the pandemic. […]
Lancet Oncol. 2021 Dec;22(12):1669-1680. doi: 10.1016/S1470-2045(21)00573-8. Epub 2021 Nov 3. ABSTRACT BACKGROUND: The medium-term and long-term impact of COVID-19 in patients with cancer is not yet known. In this study, we aimed to describe the prevalence of COVID-19 sequelae and their impact on the survival of patients with cancer. We also aimed to describe patterns […]
Am J Hematol. 2022 Jan 1;97(1):30-42. doi: 10.1002/ajh.26385. Epub 2021 Nov 2. ABSTRACT This is a multicenter prospective observational study that included a large cohort (n = 397) of allogeneic (allo-HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3-6 weeks after […]
Leuk Lymphoma. 2022 Mar;63(3):538-550. doi: 10.1080/10428194.2021.1992619. Epub 2021 Oct 20. ABSTRACT In the midst of the COVID-19 pandemic, different vaccines in front of SARS-CoV-2 have been approved and administered in different vulnerable populations. As patients with cancer were excluded from pivotal trials of vaccination, little is known on their immunogenic response to these vaccines, particularly […]
Bone Marrow Transplant. 2021 Dec;56(12):2876-2881. doi: 10.1038/s41409-021-01467-8. Epub 2021 Sep 29. ABSTRACT Quality management has been part of hematopoietic stem cell transplantation (HSCT) from the very beginning. It evolved step-wise from open data exchange up to the introduction of the FACT/JACIE-based quality management system (QMS) 2 decades ago. This formal step has eased cooperation, and […]
Research Projects
PI21/00684. Improving Outcomes of Patients with Extramedullary Multiple Myeloma. Potential Applicability of Orthoxenograft Models in the Study of Genetic Bases of Drug Resistance. ISCIII/AES. Budget: 135.520,00 euros, 2022 – 2024. PI: Anna Sureda, Co-PI: Lourdes Farre.
201941-30. Humanized nanomedicines selectively killing CXCR4+ cancer cells for Acute Myeloid Leukemia therapy. Marató TV3. Budget: 99.960,81 euros, 2020 – 2024. Projecte coordinat. Sub-projecte PI: Dra. Lourdes Farre
Collaborations
Isolda Casanova. Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Toni Villaverde. Institut de Biotecnologia i de Biomedicina. Universitat Autònoma de Barcelona, Bellaterra, Spain
Sonia Guil. Josep Carreras Leukaemia Research Institute, Badalona, Spain.
Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952
Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069
Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087
Casanovas’ Lab